Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Abstract Background The current expert view of the PCSK9 inhibitors’ use in Egypt is still ambiguous. Main body Hyperlipidemia is an important, if not the most important, risk factor for the occurrence of atherosclerosis worldwide. Egypt is the most populous country in the Middle East and North Afri...

Full description

Bibliographic Details
Main Authors: Ashraf Reda, Ahmed Shawky Elserafy, Elsayed Farag, Tamer Mostafa, Nabil Farag, Atef Elbahry, Osama Sanad, Ahmed Bendary, Ahmed Elkersh, Mohammed Selim, Morad Beshay, Hazem Khamis
Format: Article
Language:English
Published: SpringerOpen 2020-05-01
Series:The Egyptian Heart Journal
Subjects:
Egypt
Dyslipidemia
PCSK-9
Online Access:http://link.springer.com/article/10.1186/s43044-020-00058-0

Internet

http://link.springer.com/article/10.1186/s43044-020-00058-0

Similar Items